New hospital purchasing guidelines in Germany could force medtech companies to rethink traditional strategies
This article was originally published in Clinica
Executive Summary
The German market for medical devices is by no means as open to innovation as it was a few years ago. The criteria for paying for treatment by health insurers have been expanded to include cost-efficiency although the evaluation formulae have not yet been established. But, say consultants Hans-Jurgen Wildau and Bernd Grohs, potentially expensive outlays for developing innovative medical products can be reduced by integrating partners from different healthcare sectors early on.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.